Leukemia

HCRN-AML20-472

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
Status
Cancer Types
Leukemia
Locations

BTCRC-AML17-113

Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113
Status
Open to Accrual
Cancer Types
Leukemia
Locations

BTCRC-HEM17-092

Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092
Status
Closed
Cancer Types
Leukemia
Locations

BTCRC-AML18-342

Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia. Big Ten Cancer Research Consortium BTCRC-AML18-342
Status
Closed
Cancer Types
Leukemia
Locations

HCRN-CLL03-59

A Phase II Study of Ontak in Patients with Previously Treated Chronic Lymphocytic Leukemia
Status
Closed
Cancer Types
Leukemia
Locations

HCRN-HOG-06

A Randomized Phase III Study of Low-Dose Cytosine Arabinoside vs Supportive Care in the Treatment of Preleukemia
Status
Closed
Cancer Types
Leukemia
Locations